AnHorn Medicines Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
AnHorn’s flagship therapeutic modality is BIGPRO®, a bi‑functional ligand that induces targeted degradation of disease-causing proteins. Using their proprietary AIMCADD® platform (which integrates AI, bioinformatics, and medicinal chemistry), AnHorn rapid
Founded Year
2020
Unified Business No.
83523270
Status
Active
Number of Employees
0
Total Paid-in
Capital
463,770,820 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AnHorn Medicines Co., Ltd., founded in 2020 and based in Taipei, is a biotech company that designs novel therapeutics using an AI-powered drug discovery platform (AIMCADD®). Their mission is to develop a new class of protein-degrading therapies (BIGPRO®) that selectively eliminate disease-causing proteins, targeting difficult-to-treat conditions such as cancer, neurodegenerative disorders, and age-related diseases.
